Is ALK-Abelló A/S a good investment?
ALK-Abelló A/S (ALK-B.CO) is currently trading at 227.40 DKK.
Market analysts have a consensus price target of 291.00 DKK.
This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 37.51.
This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule:
ALK-Abelló A/S is expected to release its next earnings report on Nov. 17, 2026.
The market consensus estimate for Forward EPS is 7.22.
For income investors, ALK-Abelló A/S pays a dividend yield of 0.70%.
With a payout ratio of 26%, the dividend appears
sustainable.
Company Profile
ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays for emergency treatment of anaphylaxis and acute flares in chronic spontaneous urticaria; and ALK 014, a biologic for food allergies. It also provides GRAZAX/GRASTEK, a tablet for grass pollen allergy; ACARIZAX, ODACTRA, and MITICURE/SENSIMUNE, which are tablets for house dust mite allergies; ITULAZAX/ITULATEK, a tablet for tree pollen allergy; RAGWITEK/RAGWIZAX, a tablet for ragweed pollen allergy; and CEDARCURE, a tablet for Japanese cedar pollen allergy. In addition, the company offers consumer healthcare solutions, such as klarify.me, a digital patient engagement platform to help people manage their allergies. Further, it provides allergen extracts for use in the diagnosis of specific allergies, such as skin prick and blood test; and emergency medicine treatment, such as adrenaline autoinjectors, an intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. for the development of GRAZAX and CEDARCURE; and Dr. Reddy's Laboratories for the development of Sensimune. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.
Community Discussion